Why Is ORIC PHARMACEUTICALS (ORIC) Stock Moving Today?

Oric Pharmaceuticals stock is moving lower today, closing at $12.95, down from a prior close of $13.63. The primary driver is the presentation of new clinical and preclinical data at the ESMO Congress, which included results for enozertinib and rinzimetostat.

What Happened

The company filed an 8-K on October 23, 2026, disclosing Regulation FD materials and other events. Key disclosures include data for enozertinib in first-line non-small cell lung cancer patients with EGFR atypical mutations. In this population, which had more than double the rate of baseline CNS metastases compared to competitor datasets, enozertinib demonstrated an 84% confirmed systemic objective response rate and a 70% confirmed intracranial objective response rate. Oric plans to advance enozertinib into a global Phase 3 trial, designated Redwood-1, in the first half of 2027. Additionally, the company presented preclinical and translational data for rinzimetostat, an EED inhibitor. The data highlighted potential advantages of targeting PRC2 via EED over EZH2, noting the emergence of resistance mutations to EZH2 inhibitors such as mevrometostat against which rinzimetostat may be effective.

What The Data Shows

The stock opened at $13.79, a 1.2% gap up from the prior close, before hitting a session high of $13.80 at 7:00 AM ET. It subsequently declined to a session low of $12.76 at 9:55 AM ET. Volume so far stands at 0.1 million shares, which is 0.0 times the three-month daily average. The company has a market capitalization of $1.4 billion and is unprofitable, with a trailing twelve-month EPS of -1.35. The 52-week range is $7.23 to $14.68. On October 23, the stock printed two fresh 52-week highs and eight fresh 52-week lows. Recent insider activity includes six sales totaling $1.7 million over the last 90 days, with no buys. The most recent sale was by CFO Dominic Piscitelli on October 20, 2026.

What To Watch

Investors will monitor the company's plans to host a conference call and webcast to review the enozertinib data. The scheduled start of the global Phase 3 Redwood-1 trial in the first half of 2027 remains a key future catalyst for the stock.